Acumen Pharmaceuticals, Inc. (ABOS)
NASDAQ: ABOS · IEX Real-Time Price · USD
3.175
-0.015 (-0.47%)
Apr 26, 2024, 2:38 PM EDT - Market open
Acumen Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for ABOS stock have an average target of 12.6, with a low estimate of 8.00 and a high estimate of 15. The average target predicts an increase of 296.85% from the current stock price of 3.18.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 27, 2024.
Analyst Ratings
The average analyst rating for ABOS stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $15 | Strong Buy | Maintains | $15 | +372.44% | Mar 27, 2024 |
| Deutsche Bank | Deutsche Bank | Strong Buy Initiates $8 | Strong Buy | Initiates | $8 | +151.97% | Dec 12, 2023 |
| Credit Suisse | Credit Suisse | Buy Reiterates $13 | Buy | Reiterates | $13 | +309.45% | Aug 9, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +372.44% | Aug 9, 2023 |
| B of A Securities | B of A Securities | Strong Buy Initiates $14 | Strong Buy | Initiates | $14 | +340.94% | Jul 20, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.20
from -1.08
EPS Next Year
-1.43
from -1.20
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | n/a | 27.9M |
| Avg | n/a | n/a | n/a | n/a | 13.5M |
| Low | n/a | n/a | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.02 | -1.20 | -1.42 | -1.86 | -1.46 |
| Avg | -1.20 | -1.43 | -1.85 | -1.81 | -1.42 |
| Low | -1.49 | -1.95 | -2.43 | -1.73 | -1.36 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.